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Acquired Hemophilia A: A Case Report
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Case Report

A 61-year-old African American male, with a past medical
history of asthma and benign prostatic hypertrophy, presented
from an outside hospital with complaints of hematuria and
hematemesis. He had initially noted increased bruising two
months prior to admission. He also had symptoms suggestive of
a non-traumatic thigh hematoma the month prior. He developed
hematuria one month prior to admission and underwent an
outpatient cystoscopy one week prior to admission which
was non-diagnostic. Cystoscopy was repeated on the day of
admission localizing the hemorrhage to his right kidney with a
biopsy specimen suggesting a low-grade papillary neoplasm. The
patient subsequently developed hemetemesis. Emergent esophagogastroduodenoscopy (EGD) at the outside hospital revealed
a Mallory-Weiss tear. Epinephrine was injected with initial
hemostasis. EGD was repeated after transfer due to recurrent
hematamesis and clips were placed to control the hemorrhage.
The patient experienced continued hematuria requiring repeat
cystoscopy with laser ablation, as well as biopsy of the right ureter
and right mid-pole infundibulum. However, multiple repeated
biopsies failed to confirm the presence of malignancy.
On admission, he was afebrile, with a heart rate of 94 bpm, blood
pressure of 142/88mm Hg, and oxygen saturation of 100% on
room air. His physical exam was within normal limits .His initial
hemoglobin was 7.6 g/dL, white blood cell count of 9,700 cells
per cubic millimeter (cmm), and platelet count 138,000 cells
per cubic millimeter. Coagulation studies revealed an elevated
activated partial thromboplastin time (aPTT) of 76.5 seconds.
An aPTT mixing study was performed with the aPPT correcting
to 34.9 seconds (normal 23.6-35 seconds). Incubation was not
performed. Additional laboratory evaluation demonstrated
factor VIII <0.01 U/ml (normal 0.52-1.43 U/ml) and a factor
VIII antibody was detected with a measured titer of 33.3
Bethesda Units (BU). Von Willebrand antigen and activity levels
were in the normal ranges.
Given the undetectable Factor VIII level, lack of prior history
of a bleeding diathesis, and the presence of an inhibitor with a
high titer level, a diagnosis of Acquired Hemophilia A (AHA)
was made.
The initial management strategy was to control the acute
bleeding and eradicate the inhibitor. Hemostasis was initially
obtained with recombinant Factor VIIa (rFVIIa) at 90mcg/
kg every 3-4 hours episodically for major bleeding for 6-12
hours and prior to planned invasive procedures. However
due to a decrease in clinical response during the admission, it
was switched to activated Prothrombin Complex Concentrate
(aPCC), specifically factor eight inhibitor bypass activity
(FEIBA).

Immunosuppression was initiated with 60 mg of prednisone
daily.3,30,31 He continued to experience severe hematuria requiring
continuous bladder irrigation and multiple cystoscopies for
clot evacuation and laser fulguration. Five days after initiation
of prednisone, the patient failed to show significant clinical
improvement, which warranted replacement with another type of
immunosuppressive therapy. Pulsed high-dose dexamethasone
40 mg (Dex)45-49 and Rituximab35-40 were administered for a
period of four days. However, the patient had a grade 4 reaction
to the Rituximab consistent with anaphylaxis requiring cessation
of the treatment. He then received intravenous immunoglobulin
(IVIG) for two days25-27 without any clinical response.
Given his inadequate response to standard and high dose
steroids and IVIG, and a factor VIII level of 2% with an inhibitor
titer of 40 BU, oral cyclosporine was initiated on hospital day 22
and titrated to maintain a therapeutic goal of 200-400ng/ml.41-44
His hematuria gradually improved, and he required no further
transfusions.
Over the course of his 36-day hospitalization he received a total
of 22 units of pRBC, 9 units of FFP, 34 doses of rFVIIa, and 6
doses of FEIBA. He was discharged on a therapeutic dose of oral
cyclosporine with a Factor VIII level of 4% and an inhibitor titer
of 57.1 BU at the time of discharge (Graph 1).
He was evaluated weekly following discharge during which he
did not have any major hemorrhage. His cyclosporine dose was
titrated based on trough levels. He continued pulsed, high-dose
dexamethasone for 4 consecutive days every 28 days. His Factor
VIII level demonstrated gradual improvement during this period
and inhibitor levels gradually decreased. Following the fourth
cycle of high-dose dexamethasone, his Factor VIII level rose to
29% and his inhibitor level became undetectable. Dexamethasone
was discontinued following the fourth cycle after obtaining an
undetectable inhibitor level. Cyclosporine weaning was initiated
following two consecutive factor levels greater than 80%.

Discussion

Acquired Hemophilia A (AHA) is a rare condition in which
autoantibodies, usually of the IgG class, are produced against
Factor VIII. This results in low plasma Factor VIII levels. Its
incidence ranges from 0.2-4 cases/million/year according
to various reports.1,2,3,4,5 However, given the complexity of
diagnosis, the condition may be under diagnosed.11,12,15 The
incidence increases with age with a peak incidence in the 7th and
8th decade of life. There is a small peak in the 3rd decade likely
corresponding to postpartum inhibitors.3 The mortality rate is
high, ranging from 8%-22%. This is related to severe hemorrhage
that can occur in 85%-90% of the patients.3,4 Approximately half
of the cases are associated with underlying conditions including
pregnancy, autoimmune disorders, malignancy, medications,
dermatologic conditions, inflammatory bowel disease, and
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Figure 1. Factor VIII Level and Inhibitor Titer by Treatment Day

infections such as hepatitis B and C. The other half occur
without evidence of a coexisting disorder (idiopathic).3,6,7,8,9,10
This condition commonly presents with mucosal bleeding
(including epistaxis, gastrointestinal, and genitourinary),
ecchymosis, and soft tissue hemorrhage including retroperitoneal
bleeding. In contrast to congenital Hemophilia A, hemarthrosis
is rare.3,4
The diagnosis is confirmed by detection of a prolonged aPTT
which does not correct by 1:1 mixing with normal plasma (aPTT
mixing study). Occasionally, there is immediate correction
but after incubation for 2 hours at 37°C there is reversal of
the correction. Factor VIII levels are markedly reduced, and
anti-FVIII antibodies are detectable.
The primary goals of treatment for AHA are to control acute
bleeding and to suppress the autoantibody. Antibody eradication
often requires treatment of the instigating condition when present.
AHA can represent a transfusion emergency requiring intensive
transfusion support.13 In patients with high titer inhibitors (>5
BU), bypassing agents, such as FEIBA and rVIIa, are the mainstay
of therapy for acute hemorrhage.4-21 The recommended dose of
FEIBA, ranges between 50–100 U/kg administered every 6–12
hours, not to exceed a single dose of 100 U/kg or a daily dose of
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200 U/kg.3,14,15,16 In one study, FEIBA controlled hemorrhage in
86% of patients.14 The recommended dose of rVIIa ranges from
90 to 120 mcg/kg every 2-3 hours.17-21 A pooled analysis of data
of 139 patients from different sources reported an efficacy rate
of 88%.17 Venous thromboembolic disease (VTE) is an adverse
event associated with both of these agents.

Factor VIII in large doses should be considered in patients
known to have low-titer inhibitors (<5 BU). Porcine Factor
VIII from pooled plasma, while not currently available in
the US, has been used historically to increase plasma factor
VIII levels, and it takes advantage of the minimal antigenic
cross reactivity with human Factor VIII inhibitors.22,23,24 A
recombinant porcine factor VIII, B-domain deleted (OBI-1)
has recently been tested in a clinical trial in the US (50).
A number of immunosuppressive therapies have been used
to control inhibitors. However, current treatment is based on
small, uncontrolled, single-center cohorts and meta-analysis.
Corticosteroids and cytotoxic drugs, used either alone or in
combination, have been regarded as the mainstay of therapy.
An alternate modality of inhibitor suppression is IVIG;
however, this has generally been less effective.11,25,26,27 Removal
of the inhibitor via an immunoadsorption process has been
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attempted.3,28,29 But this process requires central venous access,
specialized equipment and training, and close FVIII monitoring.
Oral steroids used alone at 1 mg/kg prednisone equivalents per
day for 3–6 weeks can cause remission in one third to one half
of patients with acquired hemophilia.3,16,30,31 Cyclophosphamide
has been used as initial therapy and in refractory patients with
high-titer inhibitors (>5 BU) leading to higher remission rates
of up to two-thirds versus steroids alone.1,3,11,16,32,33 However,
a 2-year national surveillance report of acquired hemophilia
A by the UK Haemophilia Centre Doctors’ Organization
concluded that there was no difference in inhibitor eradication
or mortality between patients treated with steroids alone or with
a combination of steroids and cytotoxic agents.11
Several reports have demonstrated the effectiveness of
Rituximab in acquired hemophilia A. The general high level of
tolerance of this drug has led to initial use of this treatment.
However, there is currently no data to establish its superiority
over other treatments. The dose typically given is 375 mg/m2
infused weekly for 4 weeks and administered concomitantly
with other immunosuppressive drugs.34-39
Cyclosporine (CsA) has also been used for inhibitor
suppression.40-43 Use of CsA requires monitoring drug levels to
ensure efficacy and prevent toxicity. However, its use is limited
due to availability of other strategies such as cytotoxic drugs and
Rituximab.
We describe a case of AHA with high titer antibody that
experienced clinical deterioration on initial monotherapy with
prednisone. The patient was unable to tolerate Rituximab due
to anaphylaxis and was also refractory to IVIG.
We report a novel strategy of combining Cyclosporine with
pulsed, high dose dexamethasone at a dose of 40mg daily for four
consecutive days every 28 days. Pulsed dose dexamethasone is
an acceptable modality of immunosupression and has been used
for the treatment of Idiopathic Thrombocytopenic Purpura
(ITP), another immune-mediated hematological disorder.44-48
In general it is tolerated well, without producing the long term
effects of steroid toxicity. No randomized trials exist comparing
the efficacy and tolerability of pulse dose dexamethasone with
longer duration steroids. However, we have experienced good
results in our institution for the treatment of ITP, and this has
become our preferred first line therapeutic modality. The patient
tolerated this regimen extremely well and went into complete
remission with undetectable antibody titers after the fourth
cycle of pulse dexamethasone. He is currently in remission and
is being weaned from cyclosporine.
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